NCT06238635 - Dostarlimab and Cobolimab in Advanced Cervical Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

July 15, 2027

Conditions

Cervical CancerAdvanced Cervical CarcinomaMetastatic Cervical CancerMetastatic Cervical CarcinomaRecurrent Cervical Carcinoma

Interventions

DRUG

Dostarlimab

Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.

DRUG

Cobolimab

Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.

Trial Locations (2)

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston